Verve Therapeutics Inc (VERV)
4.79
-0.59
(-10.97%)
USD |
NASDAQ |
Nov 15, 16:00
4.79
0.00 (0.00%)
After-Hours: 20:00
Verve Therapeutics Cash and Short Term Investments (Quarterly): 539.92M for Sept. 30, 2024
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | 539.92M |
June 30, 2024 | 575.95M |
March 31, 2024 | 606.37M |
December 31, 2023 | 623.95M |
September 30, 2023 | 485.23M |
June 30, 2023 | 462.48M |
March 31, 2023 | 508.69M |
December 31, 2022 | 554.81M |
Date | Value |
---|---|
September 30, 2022 | 550.71M |
June 30, 2022 | 293.56M |
March 31, 2022 | 323.30M |
December 31, 2021 | 360.44M |
September 30, 2021 | 389.21M |
June 30, 2021 | 417.62M |
March 31, 2021 | 149.52M |
December 31, 2020 | 72.11M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
72.11M
Minimum
Dec 2020
623.95M
Maximum
Dec 2023
432.12M
Average
473.85M
Median
Cash and Short Term Investments (Quarterly) Benchmarks
Ardelyx Inc | 190.40M |
Biomarin Pharmaceutical Inc | 930.44M |
Sage Therapeutics Inc | 569.15M |
ALX Oncology Holdings Inc | 148.57M |
Immuneering Corp | 59.73M |